Post-Transplant Lymphoproliferative Disorder - 18/08/11
Doi : 10.1016/j.ccm.2005.06.014
Alison W. Loren, MD, MS a, b, Donald E. Tsai, MD, PhD a, ⁎ 
a Division of Hematology/Oncology, University of Pennsylvania School of Medicine, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA
b Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
⁎Corresponding author
Résumé |
Post-transplant lymphoproliferative disorder (PTLD) is an increasingly recognized complication of solid organ and hematopoietic stem cell transplantation. PTLD represents a spectrum of polyclonal and monoclonal lymphoproliferation, generally of B cells. Prompt diagnosis is key and requires a high index of suspicion. An increasing variety of highly effective therapies, including immune modulation via reduction in immunosuppression, monoclonal antibodies, and cellular therapy, have dramatically improved the cure rates of this once devastating disease.
Le texte complet de cet article est disponible en PDF.Plan
| This work was supported by grant no. CA76931 from the National Institutes of Health (to A.W. Loren) and by a Career Development Award from the American Society of Clinical Oncology (to D.E. Tsai). |
© 2005
Elsevier Inc. Tous droits réservés.
Vol 26 - N° 4
P. 631-645 - décembre 2005 Retour au numéro
Article précédent
- Noninfectious Pulmonary Complications of Liver, Heart, and Kidney Transplantation
- Robert M. Kotloff
- Bacterial and Mycobacterial Pneumonia in Transplant Recipients
- Leanne B. Gasink, Emily A. Blumberg
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?